(Q33946522)

30 July 2017

1 reference

title

Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab (English)

1 reference

30 July 2017

1 reference

B T Luong

1

1 reference

30 July 2017

B S Chong

series ordinal

2

1 reference

30 July 2017

D M Lowder

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

Annals of Pharmacotherapy

30 July 2017

published in

1 reference

30 July 2017

volume

34

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

743-760

1 reference

Rheumatoid arthritis. Pathophysiology and implications for therapy

30 July 2017

cites work

1 reference

The work dynamics of the person with rheumatoid arthritis.

21 January 2018

1 reference

Prognosis of functional capacity and work capacity in rheumatoid arthritis.

21 January 2018

1 reference

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

21 January 2018

Cyclooxygenases 1 and 2

1 reference

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

21 January 2018

1 reference

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

Methotrexate use in rheumatoid arthritis

21 January 2018

1 reference

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.19344

1 reference

release_r6gkcmb4vvbrzpbr5azvpii4im

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/r6gkcmb4vvbrzpbr5azvpii4im

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference